Skip to main content
SpringerLink
Log in
Book cover

Sepsis und MODS pp 495–501Cite as

Veränderungen der Hämostase bei Sepsis: disseminierte intravasale Gerinnung, Verbrauchskoagulopathie und sepsisassoziierte Purpura fulminans

  • Chapter

  • 765 Accesses

This is a preview of subscription content, log in via an institution.

eBook
USD   4.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Mavrommatis AC, Theodoridis T, Orfanidou A, Roussos C, Christopoulou-Kokkinou V, Zakynthinos S (2000) Coagulation system and platelets are fully activated in uncomplicated sepsis. Crit Care Med 28/2: 451–457

    Google Scholar 

  2. Spero JA, Lewis JH, Hasiba U (1980) Disseminated intravascular coagulation. Findings in 346 patients. Thromb Haemost 43/1: 28–33

    Google Scholar 

  3. Bernard GR, Vincent JL, Laterre PF et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344/10: 699–709

    Article  Google Scholar 

  4. Lasch HG (1970) Clinical aspects and therapy of disseminated intravascular coagulation. Hämatol Bluttransfus 9: 121–131

    PubMed  CAS  Google Scholar 

  5. Sjobring U, Ringdahl U, Ruggeri ZM (2002) Induction of platelet thrombi by bacteria and antibodies. Blood 100/13: 4470–4477

    Article  CAS  Google Scholar 

  6. Lijnen HR, Soria J, Soria C, Collen D, Caen JP (1984) Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation. Thromb Haemost 51/1: 108–109

    Google Scholar 

  7. Mosesson MW, Siebenlist KR, Voskuilen M, Nieuwenhuizen W (1998) Evaluation of the factors contributing to fibrin-dependent plasminogen activation. Thromb Haemost 79/4: 796–801

    Google Scholar 

  8. Yakovlev S, Makogonenko E, Kurochkina N, Nieuwenhuizen W, Ingham K, Medved L (2000) Conversion of fibrinogen to fibrin: mechanism of exposure of tPA-and plasminogenbinding sites. Biochemistry 39/51: 15.730–15.741

    Google Scholar 

  9. Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J (1993) Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 104/3: 882–888

    Google Scholar 

  10. Baudo F, Caimi TM, Cataldo F de et al. (1998) Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 24/4: 336–342

    Article  Google Scholar 

  11. Eisele B, Lamy M, Thijs LG et al. (1998) Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 24/7: 663–672

    Article  Google Scholar 

  12. Warren BL, Eid A, Singer P et al. (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286/15: 1869–1878

    Article  Google Scholar 

  13. Inthorn D, Hoffmann JN, Hartl WH, Muhlbayer D, Jochum M (1997) Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock 8/5: 328–334

    Google Scholar 

  14. Lasch HG, Heene DH (1975) Heparin therapy of diffuse intravascular coagulation (DIC). Thromb Diath Haemorrh 33/1: 105–106

    Google Scholar 

  15. Corrigan JJ Jr, Jordan CM (1970) Heparin therapy in septicemia with disseminated intravascular coagulation. N Engl J Med 283/15: 778–782

    Article  Google Scholar 

  16. Nishiyama T, Matsukawa T, Hanaoka K (2000) Is protease inhibitor a choice for the treatment of pre-or mild disseminated intravascular coagulation? Crit Care Med 28/5: 1419–1422

    Google Scholar 

  17. Taenaka N, Shimada Y, Hirata T et al. (1983) Gabexate mesilate (FOY) therapy of disseminated intravascular coagulation due to sepsis. Crit Care Med 11/9: 735–738

    Google Scholar 

  18. Abraham E, Reinhart K, Opal S et al. (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290/2: 238–247

    Article  Google Scholar 

  19. Vincent JL (2002) Drotrecogin alfa: a new approach in the treatment of severe sepsis. Expert Opin Biol Ther 2/6: 659–664

    Article  Google Scholar 

  20. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W (2002) Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296/5574: 1880–1882

    Article  Google Scholar 

  21. Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C (2002) An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 347/13: 993–1000

    Article  Google Scholar 

  22. Dhainaut JF, Marin N, Mignon A, Vinsonneau C (2001) Hepatic response to sepsis: interaction between coagulation and inflammatory processes. Crit Care Med 29(Suppl 7):S42–S47

    PubMed  CAS  Google Scholar 

  23. Wenzel C, Stoiser B, Locker GJ et al. (2002) Frequent development of lupus anticoagulants in critically ill patients treated under intensive care conditions. Crit Care Med 30/4: 763–770

    Google Scholar 

  24. Stephan F, Cheffi MA, Kaplan C et al. (2000) Autoantibodies against platelet glycoproteins in critically ill patients with thrombocytopenia. Am J Med 108/7: 554–560

    Google Scholar 

  25. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M (2001) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86/5: 1327–1330

    Google Scholar 

  26. Wada H, Wakita Y, Nakase T et al. (1995) Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. The DIC Study Group. Thromb Haemost 74/3: 848–852

    Google Scholar 

  27. Gando S, Nanzaki S, Kemmotsu O (1999) Disseminated intravascular coagulation and sustained systemic inflammatory response syndrome predict organ dysfunctions after trauma: application of clinical decision analysis. Ann Surg 229/1: 121–127

    Article  Google Scholar 

  28. Fox B (1971) Disseminated intravascular coagulation and the Waterhouse-Friderichsen syndrome. Arch Dis Child 46/249: 680–685

    Article  Google Scholar 

  29. Haslund R (1973) Waterhouse Friderichsen syndrome. Endotoxin shock treated with massive doses of cortisol. J Oslo City Hosp 23/3: 49–64

    Google Scholar 

  30. Auburtin M, Porcher R, Bruneel F et al. (2002) Pneumococcal meningitis in the intensive care unit: prognostic factors of clinical outcome in a series of 80 cases. Am J Respir Crit Care Med 165/5: 713–717

    Google Scholar 

  31. Lineaweaver W, Franzini D, Dragonetti D, McCarley D, Rumley T (1986) Haemophilus influenzae meningitis and Waterhouse-Friderichsen syndrome in an adult. South Med J 79/8: 1034–1036

    Google Scholar 

  32. Canpolat C, Bakir M (2002) A case of purpura fulminans secondary to transient protein C deficiency as a complication of chickenpox infection. Turk J Pediatr 44/2: 148–151

    Google Scholar 

  33. Karakousis PC, Page KR, Varello MA, Howlett PJ, Stieritz DD (2001) Waterhouse-Friderichsen syndrome after infection with group A streptococcus. Mayo Clin Proc 76/11: 1167–1170

    Article  Google Scholar 

  34. Waterhouse R (1911) A case of suprarenal apoplexy. Lancet 1911/1: 577–578

    Google Scholar 

  35. Friderichsen C (1955) Waterhouse-Friderichsen’s syndrome. Acta Endocrin 18: 482–492

    CAS  Google Scholar 

  36. Adcock DM, Hicks MJ (1990) Dermatopathology of skin necrosis associated with purpura fulminans. Semin Thromb Hemost 16/4: 283–292

    Google Scholar 

  37. Johansen K, Hansen ST Jr (1993) Symmetrical peripheral gangrene (purpura fulminans) complicating pneumococcal sepsis. Am J Surg 165/5: 642–645

    Google Scholar 

  38. Parmar MS (2002) Symmetrical peripheral gangrene: a rare but dreadful complication of sepsis. CMAJ 167/9: 1037–1038

    Google Scholar 

  39. Cohen JR, Lackner R, Keller A, Douglas B (1990) The surgical implications of purpura fulminans. Ann Vasc Surg 4/3: 276–279

    Article  Google Scholar 

  40. Silbart S, Oppenheim W (1985) Purpura fulminans. Medical, surgical, and rehabilitative considerations. Clin Orthop 193: 206–213

    PubMed  Google Scholar 

  41. Ettingshausen CE, Veldmann A, Beeg T, Schneider W, Jager G, Kreuz W (1999) Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans. Semin Thromb Hemost 25/6: 537–541

    Google Scholar 

  42. Brandtzaeg P, Sirnes K, Folsland B et al. (1985) Plasmapheresis in the treatment of severe meningococcal or pneumococcal septicaemia with DIC and fibrinolysis. Preliminary data on eight patients. Scand J Clin Lab Invest (Suppl) 178: 53–55

    CAS  Google Scholar 

  43. Churchwell KB, McManus ML, Kent P et al. (1995) Intensive blood and plasma exchange for treatment of coagulopathy in meningococcemia. J Clin Apheresis 10/4: 171–177

    Google Scholar 

  44. Dreyfus M, Masterson M, David M et al. (1995) Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Semin Thromb Hemost 21/4: 371–381

    Article  Google Scholar 

  45. Rivard GE, David M, Farrell C, Schwarz HP (1995) Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr 126/4: 646–652

    Google Scholar 

  46. Kreuz W, Veldman A, Escuriola-Ettingshausen C, Schneider W, Beeg T (1998) Protein-C concentrate for meningococcal purpura fulminans. Lancet 351/9107: 986–987; discussion 988

    Google Scholar 

  47. White B, Livingstone W, Murphy C, Hodgson A, Rafferty M, Smith OP (2000) An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 96/12: 3719–3724

    Google Scholar 

  48. Rintala E, Seppala O, Kotilainen P, Rasi V (1996) Protein C in the treatment of coagulopathy in meningococcal disease. Lancet 347/9017: 1767

    Article  Google Scholar 

  49. Rintala E, Seppala OP, Kotilainen P, Pettila V, Rasi V (1998) Protein C in the treatment of coagulopathy in meningococcal disease. Crit Care Med 26/5: 965–968

    Google Scholar 

  50. Rintala E, Kauppila M, Seppala OP et al. (2000) Protein C substitution in sepsis-associated purpura fulminans. Crit Care Med 28/7: 2373–2378

    Google Scholar 

  51. de Kleijn ED, de Groot R, Hack CE et al. (2003) Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebocontrolled, dose-finding study. Crit Care Med 31/6: 1839–1847

    Google Scholar 

  52. Hodgson A, Ryan T, Moriarty J, Mellotte G, Murphy C, Smith OP (2002) Plasma exchange as a source of protein C for acute onset protein C pathway failure. Br J Haematol 116/4: 905–908

    Article  Google Scholar 

  53. Yan SB, Dhainaut JF (2001) Activated protein C versus protein C in severe sepsis. Crit Care Med 29(Suppl 7): S69–S74

    PubMed  CAS  Google Scholar 

  54. Faust SN, Levin M, Harrison OB et al. (2001) Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 345/6: 408–416

    Article  Google Scholar 

  55. Bachli EB, Vavricka SR, Walter RB, Leschinger MI, Maggiorini M (2003) Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans. Intensive Care Med 29/2: 337

    Google Scholar 

  56. Weisel G, Joyce D, Gudmundsdottir A, Shasby DM (2002) Human recombinant activated protein C in meningococcal sepsis. Chest 121/1: 292–295

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. I. Medizinische Klinik, Fakultät für Klinische Medizin, Mannheim der Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim

    C.-E. Dempfle (Priv.-Doz. Dr.)

Authors
  1. C.-E. Dempfle
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Universitätsklinik und Poliklinik für Innere Medizin III Klinikum Kröllwitz der, Martin-Luther-Universität Halle-Wittenberg, Ernst-Grube-Str. 40, 06097, Halle/Saale

    Karl Werdan  & Ursula Müller-Werdan  & 

  2. Städtisches Krankenhaus Hildesheim, Weinberg 1, 31134, Hildesheim

    Hans-Peter Schuster

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Dempfle, CE. (2005). Veränderungen der Hämostase bei Sepsis: disseminierte intravasale Gerinnung, Verbrauchskoagulopathie und sepsisassoziierte Purpura fulminans. In: Werdan, K., Schuster, HP., Müller-Werdan, U. (eds) Sepsis und MODS. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26587-2_19

Download citation

  • DOI: https://doi.org/10.1007/3-540-26587-2_19

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-00004-4

  • Online ISBN: 978-3-540-26587-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation